Prognostic Value of Long Noncoding RNA SNHG11 in Patients with Prostate Cancer

Abstract

The present study was aimed to explore the prognostic value of long noncoding RNA SNHG11 in prostate cancer, study its expression, and assess its effect on tumor progression. One hundred and twenty prostate cancer patients and 45 cases of benign prostate hyperplasia (BPH) patients were collected. RT-qPCR was used to test the expression of SNHG11 in prostate cancer and BPH tissues, as well as in cell lines. Kaplan-Meier survival analysis and Cox regression assays were introduced to evaluate the prognostic meaning of SNHG11 in prostate cancer. The CCK-8 assays were performed to explore the effect of SNHG11 on prostate cancer cell proliferation, and a Transwell assay was conducted to access the influence of SNHG11 on prostate cancer cell migration and invasion. SNHG11 expression level was upregulated both in prostate cancer tissues and cell lines. Overexpression of SNHG11 was significantly associated with Gleason score, clinical T stage, surgical margin status, and lymph node metastasis. Patients with high SNHG11 expression levels led to a shorter overall survival time and biochemical recurrence-free survival when compared with those of low expression levels. Multivariate Cox regression results suggested that SNHG11 has the potential to act as a prognostic marker for prostate cancer patients. Knockdown of SNHG11 suppressed 22RV1 cell proliferation, migration, and invasion. In conclusion, SNHG11 is upregulated in prostate cancer patients and predicts an unfavorable prognosis for prostate cancer patients. Its knockdown can weaken prostate cancer cell metastasis and growth in vitro.

Key words

prognosis - SNHG11 - prostate cancer - proliferation - invasion

Publikationsverlauf

Eingereicht: 27. Oktober 2021

Angenommen nach Revision: 13. Januar 2022

Artikel online veröffentlicht:
11. März 2022

• References

• 1 Liu X, Yu C, Bi Y. et al. Trends and age-period-cohort effect on incidence and mortality of prostate cancer from 1990 to 2017 in China. Public Health 2019; 172: 70-80
• 2 Teoh JYC, Hirai HW, Ho JMW. et al. Global incidence of prostate cancer in developing and developed countries with changing age structures. PLoS One 2019; 14: e0221775
• 3 Schatten H. Brief overview of prostate cancer statistics, grading, diagnosis and treatment strategies. Adv Exp Med Biol 2018; 1095: 1-14
• 4 Komura K, Sweeney CJ, Inamoto T. et al. Current treatment strategies for advanced prostate cancer. Int J Urol 2018; 25: 220-231
• 5 Carlsson SV, Vickers AJ. Screening for prostate cancer. Med Clin North Am 2020; 104: 1051-1062
• 6 Albertsen PC. Prostate cancer screening and treatment: where have we come from and where are we going?. BJU Int 2020; 126: 218-224
• 7 Nassar FJ, Nasr R, Talhouk R. MicroRNAs as biomarkers for early breast cancer diagnosis, prognosis and therapy prediction. Pharmacol Ther 2017; 172: 34-49
• 8 Sun W, Yang Y, Xu C. et al. Roles of long noncoding RNAs in gastric cancer and their clinical applications. J Cancer Res Clin Oncol 2016; 142: 2231-2237
• 9 Vishnoi A, Rani S. MiRNA biogenesis and regulation of diseases: an overview. Methods Mol Biol 2017; 1509: 1-10
• 10 Pu M, Chen J, Tao Z. et al. Regulatory network of miRNA on its target: coordination between transcriptional and post-transcriptional regulation of gene expression. Cell Mol Life Sci 2019; 76: 441-451
• 11 Misawa A, Takayama KI, Inoue S. Long non-coding RNAs and prostate cancer. Cancer Sci 2017; 108: 2107-2114
• 12 You Z, Liu C, Wang C. et al. LncRNA CCAT1 promotes prostate cancer cell proliferation by interacting with DDX5 and miR-28-5p. Mol Cancer Ther 2019; 18: 2469-2479
• 13 Sun M, Geng D, Li S. et al. LncRNA PART1 modulates toll-like receptor pathways to influence cell proliferation and apoptosis in prostate cancer cells. Biol Chem 2018; 399: 387-395
• 14 Wu X, Xiao Y, Zhou Y. et al. LncRNA FOXP4-AS1 is activated by PAX5 and promotes the growth of prostate cancer by sequestering miR-3184-5p to upregulate FOXP4. Cell Death Dis 2019; 10: 472
• 15 Zhu Y, Tong Y, Wu J. et al. Knockdown of LncRNA GHET1 suppresses prostate cancer cell proliferation by inhibiting HIF-1a/Notch-1 signaling pathway via KLF2. Biofactors 2019; 45: 364-373
• 16 Wu M, Huang Y, Chen T. et al. LncRNA MEG3 inhibits the progression of prostate cancer by modulating miR-9-5p/QKI-5 axis. J Cell Mol Med 2019; 23: 29-38
• 17 Saha S, Kiran M, Kuscu C. et al. Long noncoding RNA DRAIC inhibits prostate cancer progression by interacting with IKK to inhibit NF-kB activation. Cancer Res 2020; 80: 950-963
• 18 Yu Y, Gao F, He Q. et al. lncRNA UCA1 functions as a ceRNA to promote prostate cancer progression via sponging miR143. Mol Ther Nucleic Acids 2020; 19: 751-758
• 19 Cheng R, Lu X, Xu C. et al. SNHG11 contributes to NSCLC cell growth and migration by targeting miR-485-5p/BSG axis. Biomed Pharmacother 2020; 128: 110324
• 20 Huang W, Dong S, Cha Y. et al. SNHG11 promotes cell proliferation in colorectal cancer by forming a positive regulatory loop with c-Myc. Biochem Biophys Res Commun 2020; 527: 985-992
• 21 Geng YB, Xu C, Wang Y. et al. Long non-coding RNA SNHG11 promotes cell proliferation, invasion and migration in glioma by targeting miR-154-5p. Eur Rev Med Pharmacol Sci 2020; 24: 4901-4908
• 22 Tsumura H, Satoh T, Ishiyama H. et al. Prostate-specific antigen nadir after high-dose-rate brachytherapy predicts long-term survival outcomes in high-risk prostate cancer. J Contemp Brachytherapy 2016; 8: 95-103
• 23 Herranz-Amo F. Radical retropubic prostatectomy: Origins and evolution of the technique. Actas Urol Esp 2020; 44: 408-416
• 24 Khan S, Hicks V, Rancilio D. et al. Predictors of follow-up visits post radical prostatectomy. Am J Mens Health 2018; 12: 760-765
• 25 Kinčius M, Matjošaitis AJ, Trumbeckas D. et al. Independent predictors of biochemical recurrence after radical prostatectomy: a single center experience. Cent European J Urol 2011; 64: 21-25
• 26 Martens-Uzunova ES, Böttcher R, Croce CM. et al. Long noncoding RNA in prostate, bladder, and kidney cancer. Eur Urol 2014; 65: 1140-1151
• 27 Iyer MK, Niknafs YS, Malik R. et al. The landscape of long noncoding RNAs in the human transcriptome. Nat Genet 2015; 47: 199-208
• 28 Prensner JR, Zhao S, Erho N. et al. RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1. Lancet Oncol 2014; 15: 1469-1480
• 29 Xu N, Wu YP, Yin HB. et al. Molecular network-based identification of competing endogenous RNAs and mRNA signatures that predict survival in prostate cancer. J Transl Med 2018; 16: 274
• 30 Zimta AA, Tigu AB, Braicu C. et al. An emerging class of long non-coding RNA with oncogenic role arises from the snoRNA host genes. Front Oncol 2020; 10: 389
• 31 Xiao B, Huang Z, Zhou R. et al. The prognostic value of expression of the long noncoding RNA (lncRNA) small nucleolar RNA host gene 1 (SNHG1) in patients with solid malignant tumors: A Systematic Review and Meta-Analysis. Med Sci Monit 2018; 24: 5462-5472
• 32 Avazpour N, Hajjari M, Kazemi Nezhad SR. et al. SNHG1 long noncoding RNA is potentially up-regulated in colorectal adenocarcinoma. Asian Pac J Cancer Prev 2020; 21: 897-901
• 33 Yan K, Tian J, Shi W. et al. LncRNA SNHG6 is associated with poor prognosis of gastric cancer and promotes cell proliferation and EMT through epigenetically silencing p27 and sponging miR-101-3p. Cell Physiol Biochem 2017; 42: 999-1012
• 34 Cheng D, Fan J, Ma Y. et al. LncRNA SNHG7 promotes pancreatic cancer proliferation through ID4 by sponging miR-342-3p. Cell Biosci 2019; 9: 28
• 35 Li K, Ma YB, Tian YH. et al. Silencing lncRNA SNHG6 suppresses proliferation and invasion of breast cancer cells through miR-26a/VASP axis. Pathol Res Pract 2019; 215: 152575
• 36 Guo L, Lu J, Gao J. et al. The function of SNHG7/miR-449a/ACSL1 axis in thyroid cancer. J Cell Biochem 2020; 121: 4034-4042
• 37 Yan Y, Chen Z, Xiao Y. et al. Long non-coding RNA SNHG6 is upregulated in prostate cancer and predicts poor prognosis. Mol Biol Rep 2019; 46: 2771-2778
• 38 Huang W, Huang F, Lei Z. et al. LncRNA SNHG11 promotes proliferation, migration, apoptosis, and autophagy by regulating hsa-miR-184/AGO2 in HCC. Onco Targets Ther 2020; 13: 413-421
• 39 Liu S, Yang N, Wang L. et al. lncRNA SNHG11 promotes lung cancer cell proliferation and migration via activation of Wnt/beta-catenin signaling pathway. J Cell Physiol 2020; 235: 7541-7553
• 40 Xie Q, Zhao S, Kang R. et al. lncRNA SNHG11 facilitates prostate cancer progression through the upregulation of IGF‑1R expression and by sponging miR‑184. Int J Mol Med 2021; 48: 182